A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

To join this study, you would need to meet certain requirements. You must be at least 40 years old. You also need to have been officially diagnosed with Idiopathic Pulmonary Fibrosis (IPF) by a doctor in the last eight years, and this diagnosis would be confirmed by recent lung scans. Your lung function tests, which measure how well your lungs are working, also need to be within a certain range.

There are also some reasons why you might not be able to join. For example, if you have certain other serious health conditions, or if you've recently had a bad chest infection. The study also cannot include you if you've had lung cancer, or if your lung scans show a lot of another lung condition called emphysema. If your doctor thinks you might need a lung transplant in the next six months, you also wouldn't be able to take part.

If you decide to join this study, you would be randomly assigned to one of three groups: one group will receive one dose of the new medicine, another group will receive a different dose, and the third group will receive a placebo (a dummy medicine with no active drug). You, and your study doctor, won't know which group you're in – this is called 'double-blind' and helps ensure the study results are fair.

Throughout the study, you would attend regular appointments at the study site. These visits would involve various checks, such as physical exams, blood tests, lung function tests, and possibly more scans to see how your lungs are doing. You would take the study medicine as instructed by the research team. The main treatment part of the study lasts for 24 weeks (about 6 months), and there might be follow-up checks afterwards. You would have a dedicated study team supporting you throughout your participation.